JP2015511583A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511583A5
JP2015511583A5 JP2014558972A JP2014558972A JP2015511583A5 JP 2015511583 A5 JP2015511583 A5 JP 2015511583A5 JP 2014558972 A JP2014558972 A JP 2014558972A JP 2014558972 A JP2014558972 A JP 2014558972A JP 2015511583 A5 JP2015511583 A5 JP 2015511583A5
Authority
JP
Japan
Prior art keywords
item
disease
pharmaceutical composition
weight
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014558972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511583A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/028097 external-priority patent/WO2013130669A1/en
Publication of JP2015511583A publication Critical patent/JP2015511583A/ja
Publication of JP2015511583A5 publication Critical patent/JP2015511583A5/ja
Ceased legal-status Critical Current

Links

JP2014558972A 2012-02-27 2013-02-27 薬学的組成物およびその投与 Ceased JP2015511583A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261603882P 2012-02-27 2012-02-27
US61/603,882 2012-02-27
US201261710352P 2012-10-05 2012-10-05
US61/710,352 2012-10-05
PCT/US2013/028097 WO2013130669A1 (en) 2012-02-27 2013-02-27 Pharmaceutical composition and administration thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017149148A Division JP6334041B2 (ja) 2012-02-27 2017-08-01 薬学的組成物およびその投与

Publications (2)

Publication Number Publication Date
JP2015511583A JP2015511583A (ja) 2015-04-20
JP2015511583A5 true JP2015511583A5 (cg-RX-API-DMAC7.html) 2016-04-14

Family

ID=47844520

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014558972A Ceased JP2015511583A (ja) 2012-02-27 2013-02-27 薬学的組成物およびその投与
JP2017149148A Active JP6334041B2 (ja) 2012-02-27 2017-08-01 薬学的組成物およびその投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017149148A Active JP6334041B2 (ja) 2012-02-27 2017-08-01 薬学的組成物およびその投与

Country Status (14)

Country Link
US (9) US20130224293A1 (cg-RX-API-DMAC7.html)
EP (1) EP2819670A1 (cg-RX-API-DMAC7.html)
JP (2) JP2015511583A (cg-RX-API-DMAC7.html)
CN (2) CN104470518A (cg-RX-API-DMAC7.html)
AU (1) AU2013226076B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014021090B1 (cg-RX-API-DMAC7.html)
CA (1) CA2865519C (cg-RX-API-DMAC7.html)
HK (2) HK1203840A1 (cg-RX-API-DMAC7.html)
IL (3) IL265430B2 (cg-RX-API-DMAC7.html)
MX (2) MX2014010253A (cg-RX-API-DMAC7.html)
NZ (1) NZ629199A (cg-RX-API-DMAC7.html)
RU (1) RU2692779C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013130669A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201406233B (cg-RX-API-DMAC7.html)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1664006A2 (en) 2003-09-06 2006-06-07 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
BR122018075478B8 (pt) 2004-06-24 2023-10-31 Vertex Pharma moduladores de transportadores de cassete de ligação de atp
EP1912983B1 (en) 2005-08-11 2011-06-08 Vertex Pharmaceuticals, Inc. Modulators of cystic fibrosis transmembrane conductance regulator
ES2778846T3 (es) 2005-11-08 2020-08-12 Vertex Pharma Moduladores heterocíclicos de transportadores de casete de unión a ATP
HUE032813T2 (en) 2005-12-28 2017-11-28 Vertex Pharma Solid forms of N- [2,4-bis (1,1-dimethyl ethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2006336504C9 (en) 2005-12-28 2015-05-14 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
ES2580803T3 (es) 2006-04-07 2016-08-26 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
CA2686838C (en) 2007-05-09 2017-03-14 Vertex Pharmaceuticals Incorporated Modulators of cftr
CN101827593B (zh) 2007-08-24 2013-07-24 沃泰克斯药物股份有限公司 用于治疗(特别是)囊性纤维化的异噻唑并吡啶酮
SI2217572T1 (sl) 2007-11-16 2014-05-30 Vertex Pharmaceuticals Incorporated Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
CN101910156B (zh) 2007-12-07 2013-12-04 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式
MX364936B (es) 2007-12-07 2019-05-15 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
NZ703814A (en) 2008-02-28 2016-06-24 Vertex Pharma Heteroaryl derivatives as cftr modulators
SI2615085T1 (sl) 2008-03-31 2015-11-30 Vertex Pharmaceuticals Incorporated Piridilni derivati kot cftr-modulatorji
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP2349223A2 (en) 2008-09-29 2011-08-03 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
HUE035160T2 (en) 2009-03-20 2018-05-02 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
AR081760A1 (es) 2010-04-07 2012-10-17 Vertex Pharma Una composicion farmaceutica para administracion oral que comprende acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico, un metodo para producir la misma, una tableta y una forma unitaria de dosificacion oral que la comprende y el uso de la misma para la fabricacion de un medicamento
RU2579370C2 (ru) 2010-04-07 2016-04-10 Вертекс Фармасьютикалз Инкорпорейтед Твердые формы 3-(2, 2-дифторбензо[d][1, 3] диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
MX353408B (es) 2010-04-22 2018-01-11 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
NZ603386A (en) * 2010-05-20 2015-02-27 Vertex Pharma Pharmaceutical compositions and administrations thereof
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
EP2776427B1 (en) 2011-11-08 2017-02-01 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
RU2016122882A (ru) * 2013-11-12 2017-12-19 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
MX387720B (es) 2014-04-15 2025-03-12 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quística.
RU2688191C2 (ru) * 2014-05-12 2019-05-21 ВЕРОНА ФАРМА ПиэЛСи Новое лечение
CN112279808B (zh) 2014-10-06 2024-03-08 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
MX381732B (es) 2014-11-18 2025-03-13 Vertex Pharma Proceso para efectuar la prueba de alto rendimiento de la cromatografia liquida de alta resolucion.
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CA3021752A1 (en) * 2015-06-11 2016-12-15 Aizant Drug Research Solutions Private Limited Nanoparticulate ivacaftor formulations
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
US20180353500A1 (en) 2015-09-21 2018-12-13 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
WO2017053711A2 (en) 2015-09-25 2017-03-30 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
HUP1600269A2 (hu) * 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei
US10383865B2 (en) 2016-04-25 2019-08-20 Druggability Technologies Ip Holdco Limited Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
HUP1600270A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
HUP1600271A2 (hu) * 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
US10376501B2 (en) * 2016-04-25 2019-08-13 Druggability Technologies Ip Holdco Limited Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10206915B2 (en) 2016-04-25 2019-02-19 Druggability Technologies Ip Holdco Limited Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
HUE056716T2 (hu) 2016-09-30 2022-03-28 Vertex Pharma Cisztás firbrózis transzmembrán konduktancia regulátor modulátora, gyógyszerészeti készítmények, kezelési eljárások, és eljárások a modulátor elõállítására
CN110267948B (zh) 2016-12-09 2023-12-08 弗特克斯药品有限公司 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
CA3068609A1 (en) 2017-07-01 2019-01-10 Vertex Pharmaceuticals Incorporated Compositions and methods for treatment of cystic fibrosis
CA3069225A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
JP2020537697A (ja) 2017-10-18 2020-12-24 ディーエフイー ファーマ ゲーエムベーハー ウント コー カーゲー ミニ錠
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
SG11202004264VA (en) 2017-12-01 2020-06-29 Vertex Pharma Processes for making modulators of cystic fibrosis transmembrane conductance regulator
WO2019113089A1 (en) 2017-12-04 2019-06-13 Vertex Pharmaceuticals Incorporated Compositions for treating cystic fibrosis
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) * 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
UA126304C2 (uk) 2018-02-15 2022-09-14 Вертекс Фармасьютикалз Інкорпорейтед Макроцикли як модулятори муковісцидозного трансмембранного регулятора провідності, їх фармацевтичні композиції, застосування їх для лікування муковісцидозу та спосіб їх виготовлення
WO2019195739A1 (en) 2018-04-05 2019-10-10 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
PT3880197T (pt) 2018-11-14 2023-05-09 Vertex Pharma Métodos de tratamento para a fibrose quística
AR118555A1 (es) 2019-04-03 2021-10-20 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020214921A1 (en) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cftr
EP3968955B1 (en) 2019-04-18 2025-08-27 Kinedexe UK Limited Pharmaceutical oral liquid solution of ivacaftor
WO2020242935A1 (en) 2019-05-29 2020-12-03 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN110507640A (zh) * 2019-07-19 2019-11-29 南京市儿童医院 4-苯基丁酸钠盐在制备治疗I型Bartter综合征药物中的应用
UY38837A (es) 2019-08-14 2021-02-26 Vertex Pharma Proceso de elaboración de moduladores de cftr
BR112022002605A2 (pt) 2019-08-14 2022-05-03 Vertex Pharma Formas cristalinas de moduladores de cftr
WO2021030556A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US20210069113A1 (en) * 2019-09-11 2021-03-11 Modavar Pharmaceuticals LLC Solid unit dosage form for dose individualized drug delivery
IL292471A (en) * 2019-11-01 2022-06-01 Dare Mb Inc Two-stage microchip drug delivery device and methods
EP4058028B1 (en) * 2019-11-14 2025-03-05 Celgene Corporation Pediatric formulations for treatment of cancer
WO2022194399A1 (en) 2020-07-13 2022-09-22 Idorsia Pharmaceuticals Ltd Macrocycles as cftr modulators
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
IL300413A (en) 2020-08-13 2023-04-01 Vertex Pharma Crystal forms of CFTR modulators
CN116783204A (zh) 2020-10-07 2023-09-19 弗特克斯药品有限公司 囊性纤维化跨膜传导调控因子的调节剂
US20230373939A1 (en) 2020-10-07 2023-11-23 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20230416275A1 (en) 2020-10-07 2023-12-28 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225748A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX2023004073A (es) 2020-10-07 2023-07-05 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.
WO2022076622A2 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076621A1 (en) 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225750A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20230365587A1 (en) 2020-10-07 2023-11-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US12186512B2 (en) * 2020-10-26 2025-01-07 Christopher Green Treatment for dry eyes
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
JP2023552828A (ja) 2020-12-10 2023-12-19 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症の治療方法
TW202333699A (zh) 2022-02-03 2023-09-01 美商維泰克斯製藥公司 囊腫纖維化之治療方法
JP2025505643A (ja) 2022-02-08 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子の調節因子
PE20250606A1 (es) 2022-04-06 2025-02-26 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
US20250332151A1 (en) 2022-05-16 2025-10-30 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2023320558A1 (en) 2022-08-04 2025-01-23 Vertex Pharmaceuticals Incorporated Compositions for the treatment of cftr-mediated diseases
CA3267788A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd COMBINATION OF MACROCYCLIC CFTR MODULATORS WITH CFTR CORRECTORS AND/OR CFTR POTENTIALIZERS
CA3267795A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd MACROCYCLICAL CFTR MODULATORS
WO2024056779A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide
CN115590831A (zh) * 2022-10-26 2023-01-13 力品药业（厦门）股份有限公司（Cn） 一种富马酸二甲酯缓释微片及其制备方法
WO2025076240A1 (en) 2023-10-04 2025-04-10 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cystic fibrosis transmembrane conductance regulator
WO2025076235A1 (en) 2023-10-04 2025-04-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4648753A1 (en) * 2024-02-07 2025-11-19 Vertex Pharmaceuticals Incorporated Compositions for the treatment of cftr-mediated diseases
WO2025186214A1 (en) 2024-03-05 2025-09-12 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators

Family Cites Families (323)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR960299A (cg-RX-API-DMAC7.html) 1950-04-15
DE279887C (cg-RX-API-DMAC7.html)
US3830797A (en) 1964-11-05 1974-08-20 Pennwalt Corp Tertiary-aliphatic-alpha-(peracyl)azo compounds
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US3524858A (en) 1967-05-18 1970-08-18 Warner Lambert Pharmaceutical 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
US3751406A (en) 1967-07-24 1973-08-07 Polaroid Corp Azo compounds useful in photographic processes
DE1908548A1 (de) 1968-02-29 1970-11-05 Warner Lambert Co Chinolinderivate
BE757639A (fr) 1969-10-17 1971-04-16 Roussel Uclaf Nouveaux derives de la cephalosporine et procede de preparation
AT308173B (de) 1970-02-03 1973-06-25 Maurer Friedrich Soehne Überbrückungsvorrichtung für Dehnungsfugen in Brücken od. dgl.
US4110355A (en) 1972-12-26 1978-08-29 Polaroid Corporation Anthraquinone compounds useful in photographic processes
US3931145A (en) 1972-12-27 1976-01-06 Gaf Corporation Keto-amido containing phenylazophenyl dyestuffs
GB1433774A (en) 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
GB1433151A (en) 1973-04-05 1976-04-22 Allen & Hanburys Ltd Benzo-ij-quinolizines
FR2281761A1 (fr) 1974-08-13 1976-03-12 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
FR2324304A2 (fr) 1975-09-22 1977-04-15 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
FR2340092A2 (fr) 1976-02-09 1977-09-02 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
US4221779A (en) 1977-06-28 1980-09-09 Graham Neil B Pharmaceutical composition for treating tropical diseases
DE2808070A1 (de) 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
FR2443467A1 (fr) 1978-12-08 1980-07-04 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
US4312870A (en) 1979-06-21 1982-01-26 Ciba-Geigy Corporation Pyrazoloquinolines
JPS56110612A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Readily disintegrable and absorbable compression molded article of slightly soluble drug
US4390541A (en) 1980-12-19 1983-06-28 Lilly Industries Limited Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease
HU190796B (en) 1981-06-12 1986-11-28 Roussel Uclaf,Fr Process for producing n-dihydrothiazolyl-3-quinoline-carboxamide derivatives
FR2509728A1 (fr) 1981-07-17 1983-01-21 Roussel Uclaf Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
US5281612A (en) 1982-09-09 1994-01-25 Warner-Lambert Company Naphthyridine antibacterial agents
US4638067A (en) 1982-09-09 1987-01-20 Warner-Lambert Co. Antibacterial agents
FR2537140B1 (fr) 1982-12-07 1986-07-18 Roussel Uclaf Nouveaux derives de la 4-hydroxy-3-quinoleine carboxamide, leur sels, procede de preparation, application a titre de medicaments, et compositions les renfermant
SU1360584A3 (ru) 1983-08-12 1987-12-15 Варнер-Ламберт Компани (Фирма) Способ получени нафтиридинхинолин-или бензоксазинкарбоновых кислот или их фармацевтически допустимых солей присоединени кислоты
US4845105A (en) 1984-10-30 1989-07-04 Roussel Uclaf 4-OH-quinoline carboxylic acid amides having analgesic and anti-inflammatory activity
EP0180548B1 (de) 1984-11-01 1989-06-28 Ciba-Geigy Ag Gegen Lichteinwirkung stabilisierte Ueberzugsmittel
DE3702393A1 (de) 1987-01-28 1988-08-11 Bayer Ag 8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo- 3-chinolincarbonsaeuren, verfahren zu ihrer herstellung und diese enthaltende antibakterielle mittel
US4777252A (en) 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE3731516A1 (de) 1987-09-18 1989-03-30 Bayer Ag N-aryl-stickstoffheterocyclen
DE3811341A1 (de) 1987-10-09 1989-04-27 Bayer Ag In 7-stellung c-verknuepfte chinolon- und 1,8-naphthyridin-4-on-carbonsaeure und ein verfahren zu ihrer herstellung
US4786644A (en) 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
DE3808118A1 (de) 1988-03-11 1989-09-21 Bayer Ag Verfahren zur herstellung von 1-cyclopropyl-chinoloncarbonsaeuren und deren derivaten
DE3808117A1 (de) 1988-03-11 1989-09-21 Bayer Ag N-cyclopropylaniline und deren verwendung in verfahren zur herstellung von 1-cyclopropyl-chinoloncarbonsaeuren und deren derivaten
DE3816119A1 (de) 1988-05-11 1989-11-23 Bayer Ag 7-substituierte chinolon- und naphthyridoncarbonsaeure-derivate
JPH01287066A (ja) 1988-05-13 1989-11-17 Fujimoto Seiyaku Kk 新規なアントラニル酸誘導体
DK273689A (da) 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
DE3827221A1 (de) 1988-08-11 1990-02-15 Bayer Ag Substituierte n-phenyl-stickstoff- bzw. stickstoff-schwefel-heterocyclen, verfahren sowie entsprechende heterocyclische phenolderivate, phenyliso(thio)cyanate und -carbamate als zwischenprodukte zu ihrer herstellung, ihre verwendung in herbiziden und pflanzenwuchsregulierenden mitteln
US5491139A (en) 1988-10-24 1996-02-13 The Procter & Gamble Company Antimicrobial quinolonyl lactams
DE3903799A1 (de) 1989-02-09 1990-08-16 Bayer Ag N-aryl-stickstoffheterocyclen
JPH0334977A (ja) 1989-06-29 1991-02-14 Yoshitomi Pharmaceut Ind Ltd イミダゾリルベンゾラクタム化合物
DE3924052A1 (de) 1989-07-21 1991-01-24 Bayer Ag N- (indol-6-yl)-heterocyclen
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
GB2236751B (en) 1989-10-14 1993-04-28 Wyeth John & Brother Ltd Heterocyclic compounds
LU87611A1 (fr) 1989-10-20 1991-05-07 Oreal Composition tinctoriale pour fibres keratiniques contenant des precurseurs de colorants par oxydation et des coupleurs amino indoliques,procedes de teinture mettant en oeuvre ces compositions et composes nouveaux
FR2659552B2 (fr) 1989-10-20 1994-11-04 Oreal Procede de teinture des fibres keratiniques avec des aminoindoles, composition et dispositif de mise en óoeuvre.
US5254135A (en) 1989-10-20 1993-10-19 L'oreal Methods for dyeing keratinous fibres with aminoindoles, compositions and devices for use
FR2662713B1 (fr) 1990-05-29 1994-04-08 Oreal Procede de teinture de fibres keratiniques avec un aminoindole associe a un derive quinonique.
DE4017516A1 (de) 1990-05-31 1991-12-05 Wella Ag Oxidationshaarfaerbemittel mit einem gehalt an 3-aminophenol-derivaten, verfahren zum oxidativen faerben von haaren sowie neue 3-aminophenol-derivate
US5409503A (en) 1990-05-31 1995-04-25 Wella Aktiengesellschaft Oxidation hair dye with a content of 5-aminophenyl derivatives, process for oxidative dyeing of hair and new 5-aminophenol derivatives
DE4026530A1 (de) 1990-08-22 1992-02-27 Basf Ag Synergistische mittel zur regulierung des pflanzenwachstums
US5412104A (en) 1990-09-07 1995-05-02 Schering Corporation Ester and alkoxy substituted benzopyrans
EP0550464A1 (en) 1990-09-07 1993-07-14 Schering Corporation Antiviral compounds and antihypertensive compounds
US5175151A (en) 1990-09-07 1992-12-29 Schering Corporation Antiviral compounds and antihypertensive compounds
IL100917A0 (en) 1991-02-16 1992-11-15 Fisons Plc Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
CA2065106A1 (en) 1991-04-04 1992-10-05 Junichi Fukawa Silver halide photographic light-sensitive material and photographic product for film-making process
FR2675380A1 (fr) 1991-04-18 1992-10-23 Oreal Procede de teinture des fibres keratiniques avec des aminoindoles, a ph basique, compositions mises en óoeuvre et nouveaux composes.
US5938792A (en) 1991-04-18 1999-08-17 L'oreal Process for dyeing keratinous fibers with aminoindoles and oxidation dye precursors at basic Ph's and dyeing agents
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
EP0511767A1 (en) 1991-04-29 1992-11-04 Merck & Co. Inc. Tablets containing compound DUP753
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
JPH05345780A (ja) 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
US5536727A (en) 1992-05-20 1996-07-16 Merck & Co., Inc. 17-Ethers and thioethers of 4-aza-steroids
WO1993023041A1 (en) 1992-05-20 1993-11-25 Merck & Co., Inc. Ester derivatives of 4-aza-steroids
JPH0672979A (ja) 1992-06-08 1994-03-15 Hiroyoshi Hidaka アミノベンジル誘導体
RU2047614C1 (ru) 1992-06-15 1995-11-10 Джон Вайс энд Бразер Лимитед Гетероциклические соединения, или их фармацевтически приемлемые аддитивные соли кислоты, или n-оксид гетероциклического соединения, или его аддитивная соль кислоты
US5352690A (en) 1992-07-01 1994-10-04 Eli Lilly And Company 1,2,4-trioxygenated benzene derivatives useful as leukotriene antagonists
ATE152443T1 (de) 1992-07-10 1997-05-15 Glaxo Lab Sa Anilide-derivate
US5322847A (en) 1992-11-05 1994-06-21 Pfizer Inc. Azabenzimidazoles in the treatment of asthma, arthritis and related diseases
WO1994014797A1 (en) 1992-12-23 1994-07-07 Smithkline Beecham Corporation Quinoline compounds and the treatment of leucotriene related diseases therewith
US5750754A (en) 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
JP3760474B2 (ja) 1993-04-22 2006-03-29 ダイキン工業株式会社 電気エネルギーを発生させる方法、装置およびそれに用いるｎ−ｆ結合を有する化合物
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
JPH0782498A (ja) 1993-09-17 1995-03-28 Fuji Photo Film Co Ltd ビスアゾ化合物
GB9420590D0 (en) 1993-10-22 1994-11-30 Zeneca Ltd Pyridazino quinoline compounds
JPH07179407A (ja) 1993-11-12 1995-07-18 Green Cross Corp:The 新規縮合環系化合物またはその塩、およびその医薬用途
AU7706394A (en) 1994-02-25 1995-09-11 Arrieta Munguia, Judith Marcia Quinolonylcarboxamidocephalosporin derivatives and pharmaceutical compositions containing them
FR2720397B1 (fr) 1994-05-24 1996-08-23 Laphal Laboratoires Sa Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
ITMI941099A1 (it) 1994-05-27 1995-11-27 Smithkline Beecham Farma Derivati chinolinici
ATE246677T1 (de) 1994-05-27 2003-08-15 Smithkline Beecham Farma Chinolinderivate als tachykinin nk3 rezeptor antagonisten
EP0705835A1 (de) 1994-09-01 1996-04-10 Ciba-Geigy Ag Oxa- oder thiaaliphatisch überbrückte Chinoxalin-2,3-dione
AU1106195A (en) 1994-11-09 1996-06-06 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
WO1996019239A1 (en) 1994-12-21 1996-06-27 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
JPH08301849A (ja) 1995-05-01 1996-11-19 Takeda Chem Ind Ltd ヘテロ環化合物およびその製造法
JPH0971534A (ja) 1995-06-26 1997-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
DE19601142A1 (de) 1995-07-13 1997-01-16 Agfa Gevaert Ag Verfahren zur Erzeugung eines farbigen Bildes
MX9800921A (es) 1995-08-02 1998-05-31 Chirotech Technology Ltd Quinolonas y su uso terapeutico.
US5891878A (en) 1995-08-02 1999-04-06 Chiroscience Limited Quinolones and their therapeutic use
DE19532235A1 (de) 1995-08-31 1997-03-06 Keppler Bernhard K Priv Doz Dr An Phosphonsäuren gekoppelte antibakteriell wirksame Verbindungen zur Therapie von Infektionen im Bereich des Knochens
CA2229201A1 (en) 1995-10-19 1997-04-24 Satoshi Sasaki Quinoline derivatives, their production and use
JPH09143100A (ja) * 1995-11-20 1997-06-03 Sumitomo Pharmaceut Co Ltd 服用感の改善された固形製剤
NZ325248A (en) 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
WO1997030999A1 (en) 1996-02-21 1997-08-28 Darwin Discovery Limited Quinolones and their therapeutic use
US6215016B1 (en) 1996-03-27 2001-04-10 Toray Industries, Inc. Ketone derivatives and medical application thereof
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
BR9709105A (pt) 1996-05-20 1999-08-03 Darwin Discovery Ltd Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv
AU722472B2 (en) 1996-05-20 2000-08-03 Darwin Discovery Limited Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors
PL330814A1 (en) 1996-06-20 1999-06-07 Regents Board Of Compounds for and methods of delivering pharmaceutical preparations and their application
AU3671897A (en) 1996-07-23 1998-02-10 Neurogen Corporation Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
US6069151A (en) 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
DE19651099A1 (de) 1996-12-09 1998-06-10 Consortium Elektrochem Ind Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
AU6209098A (en) 1997-01-15 1998-08-07 Novartis Ag Herbicidal agent
US5948814A (en) 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis
JP3591801B2 (ja) * 1997-06-19 2004-11-24 田辺製薬株式会社 口腔内速崩壊性製剤の製法
ZA986594B (en) 1997-07-25 1999-01-27 Abbott Lab Urokinase inhibitors
US6258822B1 (en) 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
UA60335C2 (uk) 1997-08-26 2003-10-15 Хехст Маріон Рассел, Інк. Фармацевтична композиція, яка об'єднує піперидиноалканол з протинабряковим агентом
US6429207B1 (en) 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
IL136690A0 (en) 1997-12-22 2001-06-14 Bayer Ag Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
EP1080068A1 (en) 1998-03-12 2001-03-07 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
WO1999046267A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
DE19818614A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Amide, deren Herstellung und Anwendung
JP2000016982A (ja) 1998-06-30 2000-01-18 Kumiai Chem Ind Co Ltd キノリン誘導体及びこれを有効成分とする除草剤
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
EP1101758A4 (en) 1998-07-28 2002-04-03 Nihon Nohyaku Co Ltd CONDENSED HETEROCYCLIC DICARBONIC ACID DIAMOND DERIVATIVES OR SALTS THEREOF, HERBICIDES AND THEIR USE
SI1102765T1 (en) 1998-08-03 2003-12-31 Applied Research Systems Ars Holding N.V. PROCESS FOR THE SYNTHESIS OF (1$i(H))-BENZO C)QUINOLIZIN-3-ONES DERIVATIVES
US7001770B1 (en) 1998-10-15 2006-02-21 Canji, Inc. Calpain inhibitors and their applications
FR2786483B1 (fr) 1998-12-01 2001-02-16 Rhodia Chimie Sa Procede de preparation de 4-hydroxyquinoleines et/ou formes tautomeres
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
JP2000273039A (ja) * 1999-01-20 2000-10-03 Taisho Pharmaceut Co Ltd 口腔内崩壊性組成物
DE60018225T2 (de) 1999-03-01 2005-12-29 Pfizer Products Inc., Groton Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor
JP2000256358A (ja) 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
US6413956B1 (en) 1999-05-06 2002-07-02 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
RS51019B (sr) 1999-10-25 2010-10-31 Active Biotech Ab. Lekovi za lečenje malignih tumora
DE60024861T2 (de) 1999-10-28 2006-07-06 Trine Pharmaceuticals, Inc., Waltham Pumpeninhibitoren zur freisetzung von medikamenten
JP2001199965A (ja) 1999-11-08 2001-07-24 Sankyo Co Ltd 含窒素複素環誘導体
AU1302301A (en) 1999-11-08 2001-06-06 Sankyo Company Limited Nitrogenous heterocycle derivatives
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
CO5261615A1 (es) 1999-12-01 2003-03-31 Agouron Pharma Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
AU2420001A (en) 1999-12-23 2001-07-09 Astrazeneca Ab Methods and compositions for the treatment of pain
JP2001233859A (ja) 2000-02-23 2001-08-28 Yamanouchi Pharmaceut Co Ltd 抗ヘリコバクター・ヒ゜ロリ化合物の新規製造法及びその中間体
GB0011409D0 (en) 2000-05-11 2000-06-28 Smithkline Beecham Plc Novel compounds
CA2405972C (en) 2000-05-17 2010-03-23 Gottfried Seifert Process for the preparation of aniline compounds
US6800297B2 (en) 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
WO2002003938A1 (en) 2000-06-29 2002-01-17 Clairol Incorporated Iodo-containing organic couplers for use in oxidative hair dyeing
AU6951601A (en) 2000-07-13 2002-01-30 Takeda Chemical Industries Ltd Lipid-rich plaque inhibitors
AU2001277731A1 (en) 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
WO2002038126A2 (en) 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
JP2002212179A (ja) 2001-01-15 2002-07-31 Wakunaga Pharmaceut Co Ltd 新規アニリド誘導体又はその塩及びこれを含有する医薬
GB2372986A (en) 2001-01-17 2002-09-11 Xenova Ltd 2-oxo, 4-hydroxy pyrroles and quinolines
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
DE10108271A1 (de) 2001-02-21 2002-08-22 Schering Ag Chinolin-, Isochinolin- und Phthalazinderivate als Antagonisten des Gonadotropin freisetzenden Hormons
US6515001B2 (en) 2001-03-05 2003-02-04 Chemokine Therapeutic Corporation IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
WO2002078693A2 (en) 2001-03-29 2002-10-10 Eli Lilly And Company N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor
US6878713B2 (en) 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
JP2002322054A (ja) 2001-04-26 2002-11-08 Dai Ichi Seiyaku Co Ltd 薬剤排出ポンプ阻害薬
JP2002322154A (ja) 2001-04-27 2002-11-08 Dai Ichi Seiyaku Co Ltd 抗真菌化合物
JP2002326935A (ja) 2001-05-07 2002-11-15 Sankyo Co Ltd 含窒素複素環誘導体を含有する医薬
US20050090498A1 (en) 2001-05-24 2005-04-28 Kiyohiro Samizu 3-Quinolin-2(1h)-ylideneindolin-2-one derivative
JP2003012667A (ja) 2001-06-26 2003-01-15 Rrf Kenkyusho:Kk キノリンカルボキサミド骨格を有する抗菌剤
US20030100501A1 (en) 2001-09-21 2003-05-29 Case Western Reserve University Q4N2NEG2 enhances CFTR activity
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
HRP20040510A2 (en) 2001-11-14 2005-08-31 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of losartan potassium and process for their preparation
TW200300349A (en) 2001-11-19 2003-06-01 Sankyo Co A 4-oxoqinoline derivative
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
WO2003049702A2 (en) 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2003063821A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
JP2003238413A (ja) 2002-02-14 2003-08-27 Kyowa Hakko Kogyo Co Ltd ステロイドスルファターゼ阻害剤
DE20221945U1 (de) 2002-03-15 2009-10-15 Wella Aktiengesellschaft Chinolinium-Salze enthaltende Färbemittel
US6930131B2 (en) 2002-04-10 2005-08-16 Wyeth Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM)
MXPA04010539A (es) 2002-04-26 2005-01-25 Nippon Shinyaku Co Ltd Derivados de quinazolina y medicamentos que los contienen.
US7037913B2 (en) 2002-05-01 2006-05-02 Bristol-Myers Squibb Company Bicyclo 4.4.0 antiviral derivatives
EP1506188B1 (en) 2002-05-14 2009-02-25 Xenova Limited Process for the preparation of a hydrate of an anthranilic acid derivative
KR20040107525A (ko) 2002-05-14 2004-12-20 더 리전트 오브 더 유니버시티 오브 캘리포니아 치환된 퀴놀론 카르복실산, 이들의 유도체, 그의 작용부위 및 용도
SE0201669D0 (sv) 2002-06-03 2002-06-03 Pharmacia Ab New formulation and use thereof
CA2492593A1 (en) 2002-07-15 2004-01-22 Myriad Genetics, Inc. Compounds, compositions, and methods employing same
US20040033959A1 (en) 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
MXPA05001642A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de naftaleno como inhibidores de metaloproteinasas de matriz.
TWI314041B (en) 2002-10-21 2009-09-01 Sankyo Agro Co Ltd Quinolyl-3-carboxamide compound
AR042206A1 (es) 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
JP2004189738A (ja) 2002-11-29 2004-07-08 Nippon Nohyaku Co Ltd 置換アニリド誘導体、その中間体及び農園芸用薬剤並びにその使用方法
EP1601657A1 (en) 2003-03-12 2005-12-07 Vertex Pharmaceuticals Incorporated Pyrazole modulators of atp-binding cassette transporters
WO2004105779A2 (en) 2003-05-27 2004-12-09 Cesare Montecucco Green tea and oplyphenol inhibitors of bacterial proteases
DE602004022819D1 (de) 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
US7488739B2 (en) 2003-07-24 2009-02-10 Astellas Pharma Inc. Quinolone derivative or salt thereof
CN1191252C (zh) 2003-08-11 2005-03-02 中国药科大学 3－位取代的喹诺酮衍生物及其在药学上的应用
EP1664006A2 (en) 2003-09-06 2006-06-07 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US20050059035A1 (en) 2003-09-09 2005-03-17 Quest Diagnostics Incorporated Methods and compositions for the amplification of mutations in the diagnosis of cystic fibrosis
ES2734057T3 (es) 2003-09-12 2019-12-04 Amgen Inc Formulación de disolución rápida que comprende cinacalcet HCl
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
KR20060121909A (ko) 2003-10-08 2006-11-29 버텍스 파마슈티칼스 인코포레이티드 사이클로알킬 또는 피라닐 그룹을 포함하는 ａｔｐ-결합카세트 수송자의 조절자
CA2546115C (en) 2003-11-14 2013-01-08 Ajinomoto Co., Inc. Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives
RU2006120549A (ru) 2003-11-14 2007-12-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Тиазолы и оксазолы, применяемые в качестве модуляторов транспортеров арт-связывающей кассеты
US20050208095A1 (en) 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
JP2007516259A (ja) 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
US8759335B2 (en) 2004-01-30 2014-06-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
AU2005210668A1 (en) 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
WO2005094805A1 (ja) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
JP2006206612A (ja) 2004-05-27 2006-08-10 Ono Pharmaceut Co Ltd 固形製剤用組成物
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
CN102512372A (zh) 2004-06-08 2012-06-27 沃泰克斯药物股份有限公司 药物组合物
BR122018075478B8 (pt) 2004-06-24 2023-10-31 Vertex Pharma moduladores de transportadores de cassete de ligação de atp
US20140343098A1 (en) 2004-06-24 2014-11-20 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20070218144A1 (en) * 2004-09-21 2007-09-20 Thomas Lally Multi-purpose bio-material composition
JP5385605B2 (ja) 2005-03-11 2014-01-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
CA2600869A1 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
CA2605839C (en) * 2005-04-28 2013-10-01 Eisai R & D Management Co., Ltd. Stabilized composition of a proton pump inhibitor
ATE533749T1 (de) 2005-05-24 2011-12-15 Vertex Pharma Modulatoren von atp-bindenden kassettentransportern
CN101287732A (zh) 2005-08-11 2008-10-15 沃泰克斯药物股份有限公司 囊性纤维化跨膜电导调节剂的调控剂
EP1912983B1 (en) 2005-08-11 2011-06-08 Vertex Pharmaceuticals, Inc. Modulators of cystic fibrosis transmembrane conductance regulator
JP2009511494A (ja) 2005-10-06 2009-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
ES2778846T3 (es) 2005-11-08 2020-08-12 Vertex Pharma Moduladores heterocíclicos de transportadores de casete de unión a ATP
US20120232059A1 (en) 2005-11-08 2012-09-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
US20080057047A1 (en) 2005-11-29 2008-03-06 Benedikt Sas Use of bacillus amyloliquefaciens PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
US7989430B2 (en) 2005-12-06 2011-08-02 Regents Of The University Of Minnesota Antibacterial agents
EP1979367A2 (en) 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Quinolin-4-one derivatives as modulators of abc transporters
WO2007074472A2 (en) 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
CA2635214A1 (en) 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
HUE032813T2 (en) 2005-12-28 2017-11-28 Vertex Pharma Solid forms of N- [2,4-bis (1,1-dimethyl ethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2006336504C9 (en) 2005-12-28 2015-05-14 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2013182B1 (en) 2006-03-13 2013-09-04 Kyorin Pharmaceutical Co., Ltd. Aminoquinolones as gsk-3 inhibitors
WO2007106957A1 (en) 2006-03-21 2007-09-27 Laboratoires Smb S.A. Multiple units controlled-release floating dosage forms
ES2580803T3 (es) 2006-04-07 2016-08-26 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2007124318A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
CA2652072A1 (en) 2006-05-12 2007-11-22 Vertex Pharmaceuticals Incorporated Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2007296311A1 (en) 2006-09-12 2008-03-20 Glaxo Group Limited Pharmaceutical composition comprising a plurality of mini-tablets comprising a Factor Xa inhibitor
MX2009004702A (es) 2006-11-03 2009-06-19 Vertex Pharma Derivados de azaindol como moduladores del regulador de conductancia de transmembrana de fibrosis quistica.
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
MX2009006806A (es) 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
WO2008083130A2 (en) 2006-12-26 2008-07-10 Dr. Reddy's Laboratories Limited Amorphous and crystalline form a of carvedilol phosphate
CA2686838C (en) 2007-05-09 2017-03-14 Vertex Pharmaceuticals Incorporated Modulators of cftr
JP5686596B2 (ja) 2007-05-25 2015-03-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子
WO2009023509A2 (en) 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
CN101827593B (zh) 2007-08-24 2013-07-24 沃泰克斯药物股份有限公司 用于治疗(特别是)囊性纤维化的异噻唑并吡啶酮
EP2201010B1 (en) 2007-09-14 2013-11-06 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX2010002974A (es) 2007-09-14 2010-07-29 Vertex Pharma Formas solidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4- dihidro-4-oxoquinolin-3-carboxamida.
SI2217572T1 (sl) 2007-11-16 2014-05-30 Vertex Pharmaceuticals Incorporated Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
MX364936B (es) 2007-12-07 2019-05-15 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
JP2011506331A (ja) 2007-12-07 2011-03-03 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の処方物
CN101910156B (zh) 2007-12-07 2013-12-04 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式
NZ586271A (en) 2007-12-13 2012-08-31 Vertex Pharma Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator
NZ703814A (en) 2008-02-28 2016-06-24 Vertex Pharma Heteroaryl derivatives as cftr modulators
SI2615085T1 (sl) 2008-03-31 2015-11-30 Vertex Pharmaceuticals Incorporated Piridilni derivati kot cftr-modulatorji
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
CA2733908C (en) * 2008-08-13 2017-05-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP2328609A1 (en) 2008-08-26 2011-06-08 Cystic Fibrosis Foundation Therapeutics, Inc. Rapidly disintegrating tablets comprising lipase, amylase, and protease
EP2349223A2 (en) 2008-09-29 2011-08-03 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN102227430A (zh) 2008-10-23 2011-10-26 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
US20110257223A1 (en) 2008-10-23 2011-10-20 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
EA018891B1 (ru) 2008-10-23 2013-11-29 Вертекс Фармасьютикалз, Инкорпорейтед Модуляторы регулятора трансмембранной проводимости при муковисцидозе
MX2011004374A (es) 2008-10-23 2011-05-23 Vertex Pharma Formas solidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluo rometil)fenil)-4-oxo-5-(trifluorometil)-1,4-dihidroquinolin-3-car boxamida.
CN108117546A (zh) 2008-11-06 2018-06-05 弗特克斯药品有限公司 Atp-结合盒转运蛋白调节剂
UA104876C2 (uk) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модулятори atф-зв'язувальних касетних транспортерів
JP5699090B2 (ja) 2008-12-30 2015-04-08 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
HUE035160T2 (en) 2009-03-20 2018-05-02 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
DK2408749T3 (en) 2009-03-20 2018-08-13 Vertex Pharma CYSTIC FIBROSE TRANSMEMBRAN CONDUCTOR CONTROLLER MODULATORS
MX2012003343A (es) 2009-09-17 2012-08-17 Vertex Pharma Proceso para preparar compuestos azabiciclicos.
CN102665715A (zh) 2009-10-22 2012-09-12 沃泰克斯药物股份有限公司 治疗囊性纤维化和其他慢性疾病的组合物
AU2010310617A1 (en) 2009-10-23 2012-05-24 Vertex Pharmaceuticals Incorporated Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
CN102648182A (zh) 2009-10-23 2012-08-22 沃泰克斯药物股份有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
AU2011227021A1 (en) 2010-03-19 2012-10-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
HRP20230661T1 (hr) 2010-03-25 2023-09-29 Vertex Pharmaceuticals Incorporated Sinteza i intermedijeri od (r)-1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)-n-(1-(2,3-dihidroksipropil)-6-fluoro-2-(1-hidroksi-2-metilpropan-2-il)-1h-indol-5-il) ciklopropankarboksamida
RU2579370C2 (ru) 2010-04-07 2016-04-10 Вертекс Фармасьютикалз Инкорпорейтед Твердые формы 3-(2, 2-дифторбензо[d][1, 3] диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
AR081760A1 (es) 2010-04-07 2012-10-17 Vertex Pharma Una composicion farmaceutica para administracion oral que comprende acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico, un metodo para producir la misma, una tableta y una forma unitaria de dosificacion oral que la comprende y el uso de la misma para la fabricacion de un medicamento
EP3138563A1 (en) 2010-04-22 2017-03-08 Vertex Pharmaceuticals Inc. Pharmaceutical compositions and administrations thereof
NZ603043A (en) 2010-04-22 2015-02-27 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
WO2011133956A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
MX353408B (es) 2010-04-22 2018-01-11 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
AR081920A1 (es) 2010-05-20 2012-10-31 Vertex Pharma Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica
NZ603386A (en) 2010-05-20 2015-02-27 Vertex Pharma Pharmaceutical compositions and administrations thereof
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP2585075B8 (en) * 2010-06-24 2021-09-22 ViroPharma Biologics LLC Methods of treatment for esophageal inflammation
CA2808501A1 (en) 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
JP2013536251A (ja) * 2010-08-27 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド 薬学的組成物およびその投与
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
ES2628465T3 (es) 2011-05-18 2017-08-02 Concert Pharmaceuticals Inc. Derivados deuterados de ivacaftor
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CA2853299A1 (en) 2011-11-02 2013-05-10 Vertex Pharmaceuticals Incorporated Use of (n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide) for treating cftr mediated diseases
US20140127901A1 (en) 2012-11-08 2014-05-08 Taiwan Semiconductor Manufacturing Company, Ltd. Low-k damage free integration scheme for copper interconnects
EP2776427B1 (en) 2011-11-08 2017-02-01 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2013112804A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2013185112A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
DK2914248T4 (da) 2012-11-02 2024-01-02 Vertex Pharma Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme
MY183582A (en) 2012-11-19 2021-02-26 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
RU2016122882A (ru) 2013-11-12 2017-12-19 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
MX387720B (es) 2014-04-15 2025-03-12 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quística.
CN112279808B (zh) 2014-10-06 2024-03-08 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
MX381732B (es) 2014-11-18 2025-03-13 Vertex Pharma Proceso para efectuar la prueba de alto rendimiento de la cromatografia liquida de alta resolucion.
MA41031A (fr) 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016086136A1 (en) 2014-11-26 2016-06-02 Catabasis Pharmaceuticals, Inc. Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
EP3226861A2 (en) 2014-12-05 2017-10-11 Centre National de la Recherche Scientifique (CNRS) Compounds for treating cystic fibrosis
WO2016092561A2 (en) 2014-12-09 2016-06-16 Laurus Labs Private Limited Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
GB201507926D0 (en) 2015-05-08 2015-06-24 Proqr Therapeutics N V Improved treatments using oligonucleotides
WO2016181414A1 (en) 2015-05-12 2016-11-17 Council Of Scientific & Industrial Research Process for the synthesis of ivacaftor and related compounds
TWI730959B (zh) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
CA3021752A1 (en) 2015-06-11 2016-12-15 Aizant Drug Research Solutions Private Limited Nanoparticulate ivacaftor formulations
US20180353500A1 (en) 2015-09-21 2018-12-13 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
WO2017053711A2 (en) 2015-09-25 2017-03-30 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
CN105884628B (zh) 2016-06-06 2018-06-29 上海工程技术大学 2,4-二叔丁基-5-氨基酚的制备方法
AU2017352206B2 (en) 2016-10-27 2022-03-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated CFTR potentiators
WO2018183367A1 (en) 2017-03-28 2018-10-04 Van Goor Fredrick F Methods of treating cystic fibrosis in patients with residual function mutations
SG11202004264VA (en) 2017-12-01 2020-06-29 Vertex Pharma Processes for making modulators of cystic fibrosis transmembrane conductance regulator

Similar Documents

Publication Publication Date Title
JP2015511583A5 (cg-RX-API-DMAC7.html)
RU2014139006A (ru) Фармацевтическая композиция и ее введения
JP2013501787A5 (cg-RX-API-DMAC7.html)
JP2013536231A5 (cg-RX-API-DMAC7.html)
JP2013508407A5 (cg-RX-API-DMAC7.html)
HRP20180328T1 (hr) FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE
JP2019513741A5 (cg-RX-API-DMAC7.html)
AU2022201135B2 (en) Administration of deuterated cftr potentiators
IL273752B1 (en) Ingredients, compounds and methods for increasing cftr activity
JP2011505338A5 (cg-RX-API-DMAC7.html)
RU2014134456A (ru) Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
HRP20160682T1 (hr) Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
NZ603044A (en) Pharmaceutical compositions comprising cftr modulators and administrations thereof
RU2012121168A (ru) Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида
JP2012521361A5 (cg-RX-API-DMAC7.html)
NZ616097A (en) Pyridyl derivatives as cftr modulators
JP2013508414A5 (cg-RX-API-DMAC7.html)
Denny et al. Recent developments in targeting protein misfolding diseases
RU2012147272A (ru) Фармацевтические композиции, включающие 3-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойную кислоту, и их введение
JP2013513617A5 (cg-RX-API-DMAC7.html)
NZ581259A (en) Modulators of cystic fibrosis transmembrane conductance regulator
CA3041819A1 (en) Methods of treatment with deuterated cftr potentiators
NZ746793A (en) Silicone atoms containing ivacaftor analogues
NZ592694A (en) ATP-Binding Cassette (ABC) transporters as modulators of CFTR activity
SI3091011T1 (en) Modulators of ATP conveyor belt conveyors